JP2000516971A - 抗ウイルス性直鎖状ポリマー - Google Patents
抗ウイルス性直鎖状ポリマーInfo
- Publication number
- JP2000516971A JP2000516971A JP10506371A JP50637198A JP2000516971A JP 2000516971 A JP2000516971 A JP 2000516971A JP 10506371 A JP10506371 A JP 10506371A JP 50637198 A JP50637198 A JP 50637198A JP 2000516971 A JP2000516971 A JP 2000516971A
- Authority
- JP
- Japan
- Prior art keywords
- human
- acid
- virus
- compound according
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 26
- 229920000642 polymer Polymers 0.000 title claims description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000000129 anionic group Chemical group 0.000 claims abstract description 9
- 125000002091 cationic group Chemical group 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 19
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- -1 8-octaneamido Chemical group 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 8
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 7
- 150000001408 amides Chemical group 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 230000002155 anti-virotic effect Effects 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- KHMVPPUPOGJSFK-UHFFFAOYSA-N 4-(carbamothioylamino)benzenesulfonic acid Chemical compound NC(=S)NC1=CC=C(S(O)(=O)=O)C=C1 KHMVPPUPOGJSFK-UHFFFAOYSA-N 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- JDFHYYZTUNBHCA-UHFFFAOYSA-N [4-(carbamothioylamino)phenyl]methylphosphonic acid Chemical compound NC(=S)NC1=CC=C(CP(O)(O)=O)C=C1 JDFHYYZTUNBHCA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 235000018977 lysine Nutrition 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- MFBPZROATHHERV-UHFFFAOYSA-N 4-(carbamothioylamino)naphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C(NC(=S)N)=CC(S(O)(=O)=O)=CC2=C1 MFBPZROATHHERV-UHFFFAOYSA-N 0.000 claims 1
- VHHHYFRIANJFAT-UHFFFAOYSA-N 5-(carbamothioylamino)benzene-1,3-dicarboxylic acid Chemical compound NC(=S)NC1=CC(C(O)=O)=CC(C(O)=O)=C1 VHHHYFRIANJFAT-UHFFFAOYSA-N 0.000 claims 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 150000003585 thioureas Chemical class 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229920000831 ionic polymer Polymers 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 108010039918 Polylysine Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 6
- 229920000656 polylysine Polymers 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- IVAGVEGCJPHTDR-UHFFFAOYSA-N 5-(carbamothioylamino)benzene-1,3-dicarboxylic acid;sodium Chemical compound [Na].NC(=S)NC1=CC(C(O)=O)=CC(C(O)=O)=C1 IVAGVEGCJPHTDR-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 2
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MEXAGTSTSPYCEP-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@H](N)C(O)=O MEXAGTSTSPYCEP-JEDNCBNOSA-N 0.000 description 1
- BWWSESVXVARKDY-UHFFFAOYSA-N (4-isothiocyanatophenyl)methylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=C(N=C=S)C=C1 BWWSESVXVARKDY-UHFFFAOYSA-N 0.000 description 1
- CMEKTLLACGGQGP-UDWSHUFISA-N (4S,5R,6R)-5-acetyl-5-amino-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound CC(=O)[C@@]1(N)[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CMEKTLLACGGQGP-UDWSHUFISA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JKERPIAGYYBORB-UHFFFAOYSA-N 1-hydroxypyrrolidine-2,5-dione;octanoic acid Chemical compound ON1C(=O)CCC1=O.CCCCCCCC(O)=O JKERPIAGYYBORB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FWFOGSAFCVEOFH-UHFFFAOYSA-N 4-(carbamothioylamino)benzenesulfonic acid;sodium Chemical compound [Na].NC(=S)NC1=CC=C(S(O)(=O)=O)C=C1 FWFOGSAFCVEOFH-UHFFFAOYSA-N 0.000 description 1
- NCHUMJFHIHGJQD-UHFFFAOYSA-N 4-isothiocyanatobenzenesulfonic acid;sodium;hydrate Chemical compound O.[Na].OS(=O)(=O)C1=CC=C(N=C=S)C=C1 NCHUMJFHIHGJQD-UHFFFAOYSA-N 0.000 description 1
- UPPMBIZNESALIJ-UHFFFAOYSA-N 4-isothiocyanatonaphthalene-2,7-disulfonic acid Chemical compound S=C=NC1=CC(S(O)(=O)=O)=CC2=CC(S(=O)(=O)O)=CC=C21 UPPMBIZNESALIJ-UHFFFAOYSA-N 0.000 description 1
- VKXNSANQAPEDDG-UHFFFAOYSA-N 5-isothiocyanatobenzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC(N=C=S)=CC(C(O)=O)=C1 VKXNSANQAPEDDG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AWLUSOLTCFEHNE-UHFFFAOYSA-N sodium;urea Chemical compound [Na].NC(N)=O AWLUSOLTCFEHNE-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/36—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino acids, polyamines and polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyamides (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.複数の側鎖基を有し、側鎖基の少なくともひとつにアニオン性またはカチオ ン性部分が結合又は連結している、直鎖状非炭水化物ポリマーを含有する抗ウイ ルス性化合物。 2.一般式I (式中、 Rは直鎖状ポリマー骨格を形成している非炭水化物モノマーユニットである、 XはモノマーユニットRの側鎖基上の、任意の連結基である、 Aはアニオン性含有部分である) で示される直鎖状ポリマーを含有する、請求項1の化合物。 3.直鎖状ポリマーの分子量分布のメジアン値が1,000から1,000,0 00である、請求項2記載の化合物。 4.分子量分布のメジアン値が10,000から600,000である、請求項 3記載の化合物。 5.モノマーユニットRがアミン又はアミド部分である、請求項2記載の化合物 。 6.モノマーユニットRがリシンまたは他のものである、請求項5記載の化合物 。 7.連結基Xが存在する場合、これがエステル、アミド、エーテル、チオエーテ ル、アミン、ウレア、チオウレア、カーバメートおよびカーボネートからなる群 から選択される連結性官能基である、請求項2記載の化合物。 8.連結基Xが存在する場合、任意に置換又は分岐していて良いアルキル鎖;ア ルコキシ、ポリアルコキシ、任意に置換されていてよい、アルキルチオまたはポ リアルキルチオ鎖;アルケニル、多価アルケニル、任意に置換されていてもよい アルキニル又は多価アルキニル鎖;および式-(-CH2)n-2-(-CH2)n-(式中、 Cは-CH2-、-CH=CH-、-C≡C-、-O-または-S-である。nは1から15 の 間の整数である)からなる群、から選択されるスペーサー基である、請求項2記 載の化合物。 9.アニオン性又はカチオン性部分が、直鎖状ポリマーのアミン、スルフヒドリ ル、ヒドロキシ、又は他の側鎖反応性官能基とアミド又はチオウレア結合にて結 合している、請求項1から8いずれかに記載の化合物。 10.アニオン性含有部分が、スルホン酸含有部分、ノイラミン酸およびシアル 酸、修飾ノイラミン酸およびシアル酸含有部分を含むカルボン酸含有部分、ホウ 酸含有部分、およびエステル化リン酸およびホスホン酸含有部分を含む、リン酸 およびホスホン酸含有部分、からなる群から選択される、請求項1から9いずれ かに記載の化合物。 11.側鎖基のアミノ又は他の反応性官能基に結合している部分が、以下の式(式 中、Nはゼロまたは正の整数を示す)からなる群から選択される、請求項1から 9いずれかに記載の化合物: ―NH(CH2)nSO3 - ―(CH2)nSO3 - ―AR(SO3 -)n ―CH2CH(SO3 -)COOH ―CH(SO3 -)CH2COOH ArX(CH2)nSO3 - X=O,S,NH ―(CH2)n +NMe3 ―Ar(N+Me3)n ―Ar(CH2N+Me3)n ―ArXP(=O)(OR)2 X=O,CH2,CHF,CF2R=アルキル、アリール、H,Na ―ArXP(=O)(OR1)(NR2R3) X=O,CH2,CHF,CF2 R1=アルキル、アリール,H,Na 、R2,R3=アルキル、アリール ―Ar[P(=O)(OR)2]n R=アルキル、アリール、H,Na n=1-3 ―Ar[B(OH)2]n n=1-3 ―Ar[COOH]n n=1-3 12.以下の群から選択される、請求項1または2記載の化合物: i 末端が4−スルホフェニルチオウレアであるポリL−リシン ii 末端が3,6−ジスルホナフチルチオウレアである、ポリ-L-リシン; iii 末端が(8-オクタンアミド)-5-アセトアミド-3,5-ジデオキシ-2- チオ-D−グリセロ-α-D−ガラクト-2-ノヌロピラノシディックアシッドであ る、ポリ-L-リシン; iv 末端が3,5-ジカルボキシフェニルチオウレアである、ポリ-L-リシン ; v 末端が4−(ホスフォノメチル)フェニルチオウレアである、ポリ-L-リ シン; vi 末端が1−ホスホノオキシフェニル-4−チオウレアである、ポリ-L- リシン; vii 末端が、ベンズアミド-4−ホウ酸である、ポリ-L-リシン。 13.請求項1から12に記載の化合物のいずれかを、少なくとも1の薬学また は獣医学上許容される担体もしくは希釈剤と共に含有する、ヒトまたは非ヒト動 物の予防的又は治療的抗ウイルス処置のための医薬または獣医薬組成物。 14.請求項1から12いずれかに記載の化合物の予防的もしくは治療的抗ウイ ルス有効量を、ヒト又は動物に投与することを含む、ヒトまたは非ヒト動物の予 防的もしくは治療的抗ウイルス処置方法。 15.抗ウイルス処置が、HIV−1またはHIV−2、B型またはC型肝炎、 ウシウイルス性下痢ウイルス、日本脳炎ウイルス(JEV)、ヒトインフルエン ザウイルスAおよびB、ライノウイルス、コロナウイルス、ヒトパラインフルエ ンザウイルス、呼吸器合胞体ウイルス(RSV)、水痘帯状疱疹ウイルス(VS V)、ヒトサイトメガロウイノレス(CMV)、エプステインバーウイノレス( EBV)、ヒトパピローマウイルス(HPV)、アデノウイルス、単純ヘルペス ウイルス(HSV)1型および2型、麻疹ウイルス、または水疱性口内炎ウイル ス(VSV)による感染に対する処置である、請求項14記載の方法。 16.ヒト又は非ヒト動物の予防的または治療的抗ウイルス処置のための、また は、ヒト又は非ヒト動物の予防的または治療的抗ウイルス処置のための医薬粗性 物を製造するための、請求項1から12いずれかに記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU1043 | 1996-07-17 | ||
AUPO1043A AUPO104396A0 (en) | 1996-07-17 | 1996-07-17 | Antiviral linear polymers |
PCT/AU1997/000446 WO1998003572A1 (en) | 1996-07-17 | 1997-07-17 | Antiviral linear polymers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000516971A true JP2000516971A (ja) | 2000-12-19 |
JP2000516971A5 JP2000516971A5 (ja) | 2005-03-10 |
Family
ID=3795359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10506371A Pending JP2000516971A (ja) | 1996-07-17 | 1997-07-17 | 抗ウイルス性直鎖状ポリマー |
Country Status (10)
Country | Link |
---|---|
US (1) | US6740635B2 (ja) |
EP (1) | EP0928306A4 (ja) |
JP (1) | JP2000516971A (ja) |
KR (1) | KR100589022B1 (ja) |
CN (1) | CN1163235C (ja) |
AU (2) | AUPO104396A0 (ja) |
BR (1) | BR9710376A (ja) |
CA (1) | CA2262863A1 (ja) |
NZ (1) | NZ333541A (ja) |
WO (1) | WO1998003572A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011020993A (ja) * | 2009-06-16 | 2011-02-03 | Sekisui Chem Co Ltd | Rnaウイルス感染阻止成形用組成物及びrnaウイルス感染阻止成形品 |
JP2011136977A (ja) * | 2009-06-16 | 2011-07-14 | Sekisui Chem Co Ltd | Rnaウイルス感染阻止塗料用組成物、rnaウイルス感染阻止塗料及びrnaウイルス感染阻止製品 |
US7998922B2 (en) | 1998-07-21 | 2011-08-16 | Denis Barritault | Process for treating fibroses with biocompatible polymer |
WO2013146782A1 (ja) * | 2012-03-27 | 2013-10-03 | 積水化学工業株式会社 | 繊維加工用インフルエンザウイルス感染阻止剤、これを用いた繊維製品及びその製造方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1238783A (zh) | 1996-11-14 | 1999-12-15 | 百奥塔科学管理有限公司 | 方法及其所用的新化合物 |
AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AUPR001000A0 (en) | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
US20040220139A1 (en) * | 2003-04-29 | 2004-11-04 | Sceusa Nicholas A. | Inhibiting viral infections |
DE102005056592A1 (de) * | 2005-11-25 | 2007-05-31 | Basf Ag | Herstellung und Verwendung von hochfunktionellen, hoch-oder hyperverzweigten Polylysinen |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
JP6284956B2 (ja) | 2013-02-19 | 2018-02-28 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド | 瘢痕組織の外観及び形成を改善するための方法並びに組成物 |
EP3174908B1 (en) | 2014-07-29 | 2021-12-08 | Uniwersytet Jagiellonski | Anionically modified n-sulfonic polyallylamine derivative, pharmaceutical composition comprising the n-sulfonic polyallylamine derivative as the active substance and use of the n-sulfonic polyallylamine derivative for the production of a medicine |
SG11202112332VA (en) * | 2020-04-15 | 2021-12-30 | Starpharma Pty Ltd | Method of prophylaxis of coronavirus and/or respiratory syncytial virus infection |
GB202007701D0 (en) | 2020-05-22 | 2020-07-08 | Univ Manchester | Antiviral polymers |
CN114053394B (zh) * | 2020-07-30 | 2024-06-21 | 广州朗圣药业有限公司 | 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用 |
TWI836258B (zh) * | 2020-08-21 | 2024-03-21 | 澳大利亞商星法馬私人有限公司 | 預防冠狀病毒及/或呼吸道融合病毒感染的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2182667B1 (ja) * | 1972-05-03 | 1978-03-03 | Rhone Poulenc Ind | |
HU187669B (en) * | 1982-03-31 | 1986-02-28 | Richter Gedeon Vegyeszet | Process for producing new copolymeres and salts |
JPS632901A (ja) * | 1986-06-24 | 1988-01-07 | Chisso Corp | 植物ウイルス病防除剤 |
NL8900442A (nl) * | 1989-02-22 | 1990-09-17 | Stichting Rega V Z W | Gesulfateerde vinylpolymeren in geneesmiddelen voor het behandelen van retrovirus-infecties. |
JP2909500B2 (ja) * | 1989-03-23 | 1999-06-23 | ベルレックス、ラボラトリーズ、レンコーポレイテッド | 水溶性抗高脂質血症剤として有用な官能化側鎖を有するポリアミド |
FR2669535A1 (fr) * | 1990-11-26 | 1992-05-29 | Medgenix Group Sa | Utilisation a titre de medicament de macromolecules polysulfonees. |
US5869457A (en) | 1991-03-11 | 1999-02-09 | Rijksuniversiteit Te Groningen | Modified proteins and their use for controlling viral infections |
JP2712056B2 (ja) * | 1992-01-14 | 1998-02-10 | 久光製薬株式会社 | コレステロール低下剤 |
AUPM623994A0 (en) * | 1994-06-15 | 1994-07-07 | Biomolecular Research Institute Limited | Antiviral dendrimers |
FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
US6034129A (en) | 1996-06-24 | 2000-03-07 | Geltex Pharmaceuticals, Inc. | Ionic polymers as anti-infective agents |
US6060235A (en) | 1997-09-19 | 2000-05-09 | Geltex Pharmaceuticals, Inc. | Antiviral polymers comprising acid functional groups and hydrophobic groups |
US6007803A (en) | 1997-09-19 | 1999-12-28 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin binding agents |
-
1996
- 1996-07-17 AU AUPO1043A patent/AUPO104396A0/en not_active Abandoned
-
1997
- 1997-07-17 NZ NZ333541A patent/NZ333541A/xx unknown
- 1997-07-17 CA CA002262863A patent/CA2262863A1/en not_active Abandoned
- 1997-07-17 BR BR9710376A patent/BR9710376A/pt not_active Application Discontinuation
- 1997-07-17 JP JP10506371A patent/JP2000516971A/ja active Pending
- 1997-07-17 AU AU33301/97A patent/AU730899B2/en not_active Ceased
- 1997-07-17 CN CNB971964378A patent/CN1163235C/zh not_active Expired - Fee Related
- 1997-07-17 KR KR1019997000234A patent/KR100589022B1/ko not_active IP Right Cessation
- 1997-07-17 WO PCT/AU1997/000446 patent/WO1998003572A1/en not_active Application Discontinuation
- 1997-07-17 EP EP97929037A patent/EP0928306A4/en not_active Withdrawn
-
2001
- 2001-08-15 US US09/929,014 patent/US6740635B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7998922B2 (en) | 1998-07-21 | 2011-08-16 | Denis Barritault | Process for treating fibroses with biocompatible polymer |
US8476220B2 (en) | 1998-07-21 | 2013-07-02 | Denis Barritault | Biocompatible polymers, process for their preparation and compositions containing them |
US8883715B2 (en) | 1998-07-21 | 2014-11-11 | Denis Barritault | Biocompatible polymers, process for their preparation and compositions containing them |
JP2011020993A (ja) * | 2009-06-16 | 2011-02-03 | Sekisui Chem Co Ltd | Rnaウイルス感染阻止成形用組成物及びrnaウイルス感染阻止成形品 |
JP2011136977A (ja) * | 2009-06-16 | 2011-07-14 | Sekisui Chem Co Ltd | Rnaウイルス感染阻止塗料用組成物、rnaウイルス感染阻止塗料及びrnaウイルス感染阻止製品 |
JP5150763B2 (ja) * | 2009-06-16 | 2013-02-27 | 積水化学工業株式会社 | インフルエンザウイルス感染阻止剤及びインフルエンザウイルス感染阻止製品 |
WO2013146782A1 (ja) * | 2012-03-27 | 2013-10-03 | 積水化学工業株式会社 | 繊維加工用インフルエンザウイルス感染阻止剤、これを用いた繊維製品及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1998003572A1 (en) | 1998-01-29 |
EP0928306A4 (en) | 2003-04-16 |
EP0928306A1 (en) | 1999-07-14 |
AU3330197A (en) | 1998-02-10 |
NZ333541A (en) | 2000-09-29 |
CN1225653A (zh) | 1999-08-11 |
BR9710376A (pt) | 1999-08-17 |
KR100589022B1 (ko) | 2006-06-13 |
AU730899B2 (en) | 2001-03-15 |
CN1163235C (zh) | 2004-08-25 |
AUPO104396A0 (en) | 1996-08-08 |
US6740635B2 (en) | 2004-05-25 |
CA2262863A1 (en) | 1998-01-29 |
KR20000067865A (ko) | 2000-11-25 |
US20020025919A1 (en) | 2002-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000516971A (ja) | 抗ウイルス性直鎖状ポリマー | |
JP4589851B2 (ja) | 抗ウイルス性デンドリマー | |
EP1580216B1 (en) | High-molecular weight derivatives of camptothecins | |
AU2007345952C1 (en) | Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates | |
EP1484059B1 (en) | Antiviral compositions comprising phenylacetic acid derivatives | |
EA032034B1 (ru) | Наночастицы двукратно дериватизованного хитозана и способы их получения и применения для переноса генов in vivo | |
WO2002094256A1 (en) | Lysine and/or analogues and/or polymers thereof for promoting wound healing and angiogenesis | |
JP5465182B2 (ja) | ポリアルキレンイミンを含むウイルス感染症治療薬 | |
EP0119757B1 (en) | Guanine derivatives, compositions containing them, and their anti-viral use | |
JPH02108624A (ja) | 抗hiv作用を有するヘパリンフラグメント及びフラクション | |
JP7502468B2 (ja) | コロナウイルス感染症の治療及び予防 | |
Olsen et al. | Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice | |
JPS63145279A (ja) | 医薬品生成物 | |
MXPA99000656A (en) | Linear polymers antivira | |
JP2003510271A (ja) | ヌクレオシドアナログを使用したウィルス感染の処置または予防のための方法 | |
MX2013003341A (es) | Formulaciones para el factor estimulante de colonia de granulocito de bovino y sus variantes. | |
WO2021211487A1 (en) | Compositions and methods of treating covid-19 with heparin or other negatively charged molecules | |
CN117582399A (zh) | 一种基于tmem16a抑制剂的小分子水凝胶及其制备方法和应用 | |
JPS5925329A (ja) | インタ−フエロン誘起剤 | |
WO1996014848A1 (en) | Novel medicinal use | |
CN112691094A (zh) | 防治病毒的新型化合物及其应用 | |
BE903368A (nl) | Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten | |
JPH07238022A (ja) | インターフェロン作用効果増強剤 | |
JPH0840916A (ja) | 3ーオキシゲルミルプロピオン酸化合物を主成分とする疣贅の発症予防及び治療剤 | |
JPH04208224A (ja) | 抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040621 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051101 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070327 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070308 |